Vertex Stock Jumps. What Wall Street Is Saying About Its Kidney Drug Trial. | MarketWire

Vertex Pharmaceuticals stock was rallying on Tuesday after positive results from a trial of its drug treating a rare kidney disease impressed Wall Street. Shares rose 5.3% to $485.10 in premarket tr

Read full article on MarketWire